TY - JOUR
T1 - Alteplase in acute ischemic stroke
T2 - Putting the guidelines into practice
AU - Nagaraja, Nandakumar
AU - Adams, Harold P.
N1 - Funding Information:
Acknowledgments/Conflicts of interest Harold P. Adams Jr. MD—Dr. Adams has grant support from NINDS and St Jude Medical. He reviews outcome events for clinical trials sponsored by Merck and serves on the Data and Safety Monitoring Board for a clinical study funded by Medtronic. He is a consultant to Pierre Fabre (France).
Publisher Copyright:
© 2014 Springer International Publishing Switzerland.
PY - 2014/11
Y1 - 2014/11
N2 - Intravenous recombinant tissue plasminogen activator (rt-PA or alteplase) is the only approved medical intervention for treatment of acute ischemic stroke within the first hours of symptom onset. In this article, we review the preliminary studies of rt-PA in acute ischemic stroke that led to US FDA approval of its use within 3 h of symptom onset. The studies on rt-PA for use beyond 3 h of symptom onset and future reperfusion therapies are discussed. Overviews of the clinical presentation and treatment of acute ischemic stroke and stroke systems of care are described.
AB - Intravenous recombinant tissue plasminogen activator (rt-PA or alteplase) is the only approved medical intervention for treatment of acute ischemic stroke within the first hours of symptom onset. In this article, we review the preliminary studies of rt-PA in acute ischemic stroke that led to US FDA approval of its use within 3 h of symptom onset. The studies on rt-PA for use beyond 3 h of symptom onset and future reperfusion therapies are discussed. Overviews of the clinical presentation and treatment of acute ischemic stroke and stroke systems of care are described.
UR - http://www.scopus.com/inward/record.url?scp=84922003392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922003392&partnerID=8YFLogxK
U2 - 10.1007/s40263-014-0204-0
DO - 10.1007/s40263-014-0204-0
M3 - Review article
C2 - 25326784
AN - SCOPUS:84922003392
VL - 28
SP - 1035
EP - 1045
JO - CNS Drugs
JF - CNS Drugs
SN - 1172-7047
IS - 11
ER -
